CA2969178A1 - Cd38 inhibitors and methods of treatment - Google Patents

Cd38 inhibitors and methods of treatment Download PDF

Info

Publication number
CA2969178A1
CA2969178A1 CA2969178A CA2969178A CA2969178A1 CA 2969178 A1 CA2969178 A1 CA 2969178A1 CA 2969178 A CA2969178 A CA 2969178A CA 2969178 A CA2969178 A CA 2969178A CA 2969178 A1 CA2969178 A1 CA 2969178A1
Authority
CA
Canada
Prior art keywords
mmol
cyclohexyl
indole
reaction
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2969178A
Other languages
English (en)
French (fr)
Inventor
David J. Becherer
Rodolfo Cadilla
David Norman Deaton
Curt Haffner
Brad Richard Henke
Frank PREUGSCHAT
Christie SCHULTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CA2969178A1 publication Critical patent/CA2969178A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2969178A 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment Abandoned CA2969178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086844P 2014-12-03 2014-12-03
US62/086,844 2014-12-03
PCT/IB2015/058965 WO2016087975A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
CA2969178A1 true CA2969178A1 (en) 2016-06-09

Family

ID=54708091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2969178A Abandoned CA2969178A1 (en) 2014-12-03 2015-11-19 Cd38 inhibitors and methods of treatment

Country Status (11)

Country Link
US (1) US9840496B2 (enExample)
EP (1) EP3227275B1 (enExample)
JP (1) JP6550132B2 (enExample)
KR (1) KR20170090478A (enExample)
CN (1) CN107428733A (enExample)
AU (1) AU2015356721B2 (enExample)
BR (1) BR112017011642A2 (enExample)
CA (1) CA2969178A1 (enExample)
ES (1) ES2717260T3 (enExample)
RU (1) RU2017121002A (enExample)
WO (1) WO2016087975A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3544612A4 (en) 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
US11535621B2 (en) * 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
US20230025807A1 (en) * 2019-10-30 2023-01-26 Mitobridge Inc. Cd38 inhibitors
KR20230051425A (ko) * 2020-04-07 2023-04-18 미토브리지, 인크. Cd38 억제제
IL301991A (en) * 2020-10-09 2023-06-01 Napa Therapeutics Ltd Heteroaryl amide inhibitors for CD38
EP4263524A1 (en) 2020-12-21 2023-10-25 Cytokinetics, Inc. Pyrazole derivatives useful as nampt modulators
AR124718A1 (es) 2021-01-29 2023-04-26 Ribon Therapeutics Inc Quinolinas y azaquinolinas como inhibidores de cd38
EP4288053A4 (en) 2021-02-08 2024-12-18 Ohio State Innovation Foundation Small molecule inhibitors of cd38 as immunosuppressants
CN117715897A (zh) * 2021-04-30 2024-03-15 南京艾美斐生物医药科技有限公司 化合物及其作为cd38抑制剂的用途
US20230116972A1 (en) * 2021-07-12 2023-04-20 Cytokinetics, Inc. Cd38 modulators and methods of use thereof
EP4724430A1 (en) * 2023-06-07 2026-04-15 Flagship Pioneering Innovations VI, LLC Condensed azines as inhibitors of cyclic adp ribose hydrolase
WO2026000074A1 (en) * 2024-06-25 2026-01-02 Welnx Company Inc. Use of cd38 inhibitors for reducing th2 inflammation
WO2026075971A1 (en) 2024-10-01 2026-04-09 Neolaia Inc. Combination therapy for treatment of metabolic disorders and inflamation related disorders using incretin compounds and cd38 inhibitors
WO2026090190A1 (en) * 2024-10-22 2026-04-30 Aeovian Pharmaceuticals, Inc. Cd38 modulators and uses thereof
CN119775288B (zh) * 2024-12-31 2025-10-10 浙江工业大学 一种cd38抑制化合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370139A4 (en) * 2001-01-04 2010-09-22 Einstein Coll Med INHIBITORS OF ADP-RIBOSYLTRANSFERASES, CYCLASES AND HYDROLASES AND THEIR USE
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
WO2010025235A1 (en) * 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors

Also Published As

Publication number Publication date
BR112017011642A2 (pt) 2018-03-06
US20170260164A1 (en) 2017-09-14
EP3227275A1 (en) 2017-10-11
WO2016087975A1 (en) 2016-06-09
RU2017121002A3 (enExample) 2019-03-15
ES2717260T3 (es) 2019-06-20
AU2015356721B2 (en) 2018-03-15
AU2015356721A1 (en) 2017-06-08
RU2017121002A (ru) 2019-01-11
US9840496B2 (en) 2017-12-12
EP3227275B1 (en) 2019-01-02
CN107428733A (zh) 2017-12-01
JP2018501215A (ja) 2018-01-18
JP6550132B2 (ja) 2019-07-24
KR20170090478A (ko) 2017-08-07

Similar Documents

Publication Publication Date Title
AU2015356721B2 (en) CD38 inhibitors and methods of treatment
EP2755958B1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
CN110078741B (zh) 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
AU2014368368C1 (en) Piperazine derivatives having multimodal activity against pain
CN108727307A (zh) 化合物及其使用方法
EP4105208A1 (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
IL279260B1 (en) Kdm1a inhibitors for the treatment of disease
UA80184C2 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
EA029644B1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
CN111269217B (zh) 一种嘧啶胺类化合物、其制备方法及应用
UA125631C2 (uk) Нові модулятори 5-гідрокситриптамінового рецептора 7 і спосіб їх застосування
KR20240074904A (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
US9271959B2 (en) Bicyclic tetrahydropyrrole compounds
US8912183B2 (en) Substituted pyridazine derivatives
WO2018021977A1 (en) Glycine metabolism modulators and uses thereof
Kabir et al. Novel anthraquinone derivatives as dual inhibitors of topoisomerase 2 and casein kinase 2: in silico studies, synthesis and biological evaluation on leukemic cell lines
KR20200097771A (ko) Akt 억제제로서의 염 형태 및 이의 결정 형태
CN101258133A (zh) 嘧啶衍生物和它们作为kcnq钾通道开放剂的用途
JP2020505401A (ja) イミダゾピリダジン化合物
CN118359542A (zh) 一种多取代的吡唑类化合物及其制备方法和用途
EP0782988A1 (en) Indole derivatives
HK1149554B (en) Substituted pyridazine derivatives which have histamine h3 antagonist activity

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831